Bristol-Myers Squibb

Trials 25

1. A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozy… Study director NCT07492680↗
2. A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors Study director NCT06764771↗
3. A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabi… Study director NCT07076121↗
4. A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid M… Study director NCT07223047↗
5. A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors Study director NCT06544655↗
6. Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation Study director NCT05737706↗
7. A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid T… Study director NCT06024174↗
8. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion Study director NCT05245500↗
9. A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Study director NCT05298592↗
10. A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors Study director NCT05625412↗
11. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors Study director NCT04895709↗
12. A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Study director NCT04943900↗
13. Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Study director NCT05001516↗
14. Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) Study director NCT04330664↗
15. Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Study director NCT03785249↗
16. A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast … Study director NCT03098550↗
17. A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors Study director NCT03184870↗
18. Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors Study director NCT02472977↗
19. Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Study director NCT01964430↗
20. A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Study director NCT01928394↗
21. Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) Study director NCT01046864↗
22. Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Study director NCT01177397↗
23. Multiple Ascending Dose (MDX1105-01) Study director NCT00729664↗
24. Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Study director NCT00633789↗
25. A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer Study director NCT00383149↗